Cargando…
Sorafenib promotes hepatocellular carcinoma invasion via interleukin-6/HIF-1α/PFKFB3
Background: Although sorafenib is adopted as the first-line treatment for unresectable liver cancer, the antitumor efficacy is severely limited by the pro-invasive side effect. Methods: To explore the underlying mechanisms, various-dosage sorafenib was applied to survey its effect on cell invasion i...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Ivyspring International Publisher
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10355201/ https://www.ncbi.nlm.nih.gov/pubmed/37476196 http://dx.doi.org/10.7150/jca.84451 |